Medicina clinica (English ed.)最新文献

英文中文

Knowledge about the chain of survival after out-of-hospital cardiac arrest among the citizens of a Spanish region 西班牙某地区居民对院外心脏骤停后存活链的认识

Medicina clinica (English ed.)

Pub Date : 2024-09-11 DOI: 10.1016/j.medcle.2024.04.012

Jose Manuel Rabanal Llevot , Francisco Ramos Goicoechea , Juan Carlos Díaz de Téran , Juan Fernando Bermejo Zubelzu

引用次数: 0

Groove pancreatitis: Case report 槽沟胰腺炎病例报告

Medicina clinica (English ed.)

Pub Date : 2024-09-11 DOI: 10.1016/j.medcle.2024.03.021

Antonio Bustos-Merlo, Antonio Rosales-Castillo, Pedro Alberto Alarcón-Blanco

引用次数: 0

Eosinophilic granulomatosis with polyangiitis: A rare case of central airway stenosis with normal eosinophil levels 嗜酸性粒细胞肉芽肿伴多血管炎：一例嗜酸性粒细胞水平正常的罕见中央气道狭窄病例

Medicina clinica (English ed.)

Pub Date : 2024-09-10 DOI: 10.1016/j.medcle.2024.03.015

Long-zhao Li , Kai Sun , Hong-wu Wang

引用次数: 0

Personalized dosage of Givosiran in acute intermittent porphyria 治疗急性间歇性卟啉症的吉沃西兰个性化剂量

Medicina clinica (English ed.)

Pub Date : 2024-09-10 DOI: 10.1016/j.medcle.2024.03.016

Manuel Garrido Montes, Roberto Pertusa Mataix, Jose Salvador Garcia Morillo

引用次数: 0

Marine–Lenhart syndrome as a cause of thyrotoxicosis: A case report Marine-Lenhart综合征是甲状腺毒症的病因之一：病例报告

Medicina clinica (English ed.)

Pub Date : 2024-09-10 DOI: 10.1016/j.medcle.2024.02.017

Rosanna del Carmen Zambrano-Infantino, Noelia Álvarez-Mena, Francisco Sebastián-Palacid

引用次数: 0

Medicina clinica (English ed.)

Pub Date : 2024-09-10 DOI: 10.1016/j.medcle.2024.03.017

Pablo Martínez Calabuig , Jorge Juan Fragío Gil , Roxana González Mazarío , Fernando López Gutiérrez , Javier Loricera García , Ricardo Blanco Alonso , Cristina Campos Fernández

Background

IgG4-related disease (IgG4-RD) is a rare, systemic immune-mediated fibro-inflammatory condition with an unclear etiology and pathophysiology, potentially affecting multiple organs. It presents with common clinical, radiological, and serological characteristics. This study aims to compare the latest two IgG4-RD classification and diagnostic criteria: Umehara–Okazaki 2011 and ACR/EULAR 2019.

Material and methods

In a retrospective cross-sectional study conducted across two centers from January 2010 to July 2023, we included patients suspected of having IgG4-RD from various hospital departments. Patients finally diagnosed with other pathologies were excluded. The remaining suspected IgG4-RD cases were evaluated using both Umehara–Okazaki 2011 and ACR/EULAR 2019 criteria.

Results

Out of 34 patients with a clinical diagnosis of IgG4-RD, the Umehara–Okazaki 2011 classified 20 patients: 5 as definitive, 7 as probable, and 8 as possible cases. Applying the ACR/EULAR 2019 criteria to the same cohort resulted in the diagnosis of 9 patients. Notably, retroperitoneal fibrosis and aortitis were the most prevalent form of presentation, accounting for 25% and 22.2% of cases classified under the 2011 and 2019 criteria, respectively.

Discussion

The more recent and stringent ACR/EULAR 2019 criteria focus on histopathology, various forms of presentation, and analytical data, allow for a more accurate classification of patients.

背景IgG4相关疾病（IgG4-RD）是一种罕见的全身性免疫介导的纤维炎症，病因和病理生理学尚不清楚，可能影响多个器官。它具有常见的临床、放射学和血清学特征。本研究旨在比较最新的两种 IgG4-RD 分类和诊断标准：材料和方法在 2010 年 1 月至 2023 年 7 月期间，我们在两个中心开展了一项回顾性横断面研究，纳入了来自不同医院科室的疑似 IgG4-RD 患者。最终确诊为其他病症的患者被排除在外。剩余的 IgG4-RD 疑似病例采用 Umehara-Okazaki 2011 和 ACR/EULAR 2019 标准进行评估：5例为确诊病例，7例为可能病例，8例为可能病例。将 ACR/EULAR 2019 标准应用于同一队列，结果有 9 名患者被确诊。值得注意的是，腹膜后纤维化和主动脉炎是最常见的表现形式，分别占 2011 年和 2019 年标准下分类病例的 25% 和 22.2%。讨论最新和更严格的 ACR/EULAR 2019 年标准侧重于组织病理学、各种表现形式和分析数据，可对患者进行更准确的分类。

{"title":"IgG4-related disease: Effectiveness evaluation through Umehara–Okazaki 2011 and ACR/EULAR 2019 diagnostic criteria","authors":"Pablo Martínez Calabuig , Jorge Juan Fragío Gil , Roxana González Mazarío , Fernando López Gutiérrez , Javier Loricera García , Ricardo Blanco Alonso , Cristina Campos Fernández","doi":"10.1016/j.medcle.2024.03.017","DOIUrl":"10.1016/j.medcle.2024.03.017","url":null,"abstract":"<div><h3>Background</h3><p>IgG4-related disease (IgG4-RD) is a rare, systemic immune-mediated fibro-inflammatory condition with an unclear etiology and pathophysiology, potentially affecting multiple organs. It presents with common clinical, radiological, and serological characteristics. This study aims to compare the latest two IgG4-RD classification and diagnostic criteria: Umehara–Okazaki 2011 and ACR/EULAR 2019.</p></div><div><h3>Material and methods</h3><p>In a retrospective cross-sectional study conducted across two centers from January 2010 to July 2023, we included patients suspected of having IgG4-RD from various hospital departments. Patients finally diagnosed with other pathologies were excluded. The remaining suspected IgG4-RD cases were evaluated using both Umehara–Okazaki 2011 and ACR/EULAR 2019 criteria.</p></div><div><h3>Results</h3><p>Out of 34 patients with a clinical diagnosis of IgG4-RD, the Umehara–Okazaki 2011 classified 20 patients: 5 as definitive, 7 as probable, and 8 as possible cases. Applying the ACR/EULAR 2019 criteria to the same cohort resulted in the diagnosis of 9 patients. Notably, retroperitoneal fibrosis and aortitis were the most prevalent form of presentation, accounting for 25% and 22.2% of cases classified under the 2011 and 2019 criteria, respectively.</p></div><div><h3>Discussion</h3><p>The more recent and stringent ACR/EULAR 2019 criteria focus on histopathology, various forms of presentation, and analytical data, allow for a more accurate classification of patients.</p></div>","PeriodicalId":74154,"journal":{"name":"Medicina clinica (English ed.)","volume":"163 5","pages":"Pages 217-223"},"PeriodicalIF":0.0,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142162732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Association between adipophilin expression and risk of dyslipidaemia in patients with granuloma annulare 环状肉芽肿患者脂肪蛋白表达与血脂异常风险之间的关系

Medicina clinica (English ed.)

Pub Date : 2024-09-10 DOI: 10.1016/j.medcle.2024.01.041

Javier Antoñanzas , Jorge María Núñez-Córdoba , Rafael Salido-Vallejo , Laura Álvarez-Gigli , Ramón Robledano , Agustín España

Background

An association between granuloma annulare (GA) and dyslipidaemia has been reported. Adipophilin expression may play a plausible role as a cutaneous biomarker for dyslipidaemia in patients with GA; however, this potential link remains to be explored.

Methods

Patients with GA were identified at our hospital between January 1, 1990, and December 31, 2021, with a thorough review of their clinical and histological characteristics. Adipophilin staining was assessed in biopsies of GA lesions.

Results

A total of 107 patients with GA were included. The prevalence of dyslipidaemia in patients with positive adipophilin staining was clearly higher than in those with negative labelling (62.3% vs 13.3%). Relative to the dyslipidaemia risk for patients with negative adipophilin expression, the odds for patients with positive adipophilin expression were increased 10-fold (OR: 10.8; p-value < .01). We identified 23 incident cases of dyslipidaemia over a median follow-up period of 91 months among 54 patients with no history of dyslipidaemia. The patients with positive adipophilin expression showed a higher risk of developing dyslipidaemia (HR: 8.9; p-value < .01).

Conclusions

Patients with positive adipophilin staining in their GA biopsies were found to be associated with a higher risk for both baseline and incident dyslipidaemia.

背景据报道，环状肉芽肿（GA）与血脂异常之间存在关联。嗜脂素的表达可能是GA患者血脂异常的皮肤生物标志物，但这种潜在的联系仍有待探索。方法对1990年1月1日至2021年12月31日期间我院收治的GA患者进行鉴定，并对其临床和组织学特征进行全面审查。结果共纳入 107 名 GA 患者。脂肪素染色阳性患者的血脂异常发生率明显高于阴性患者（62.3% 对 13.3%）。相对于嗜脂素阴性患者的血脂异常风险，嗜脂素阳性患者的血脂异常风险增加了 10 倍（OR：10.8；p-value <.01）。在中位 91 个月的随访期间，我们在 54 名无血脂异常病史的患者中发现了 23 例血脂异常病例。结论在 GA 活检中发现嗜脂素染色阳性的患者患基线和偶发血脂异常的风险较高。

{"title":"Association between adipophilin expression and risk of dyslipidaemia in patients with granuloma annulare","authors":"Javier Antoñanzas , Jorge María Núñez-Córdoba , Rafael Salido-Vallejo , Laura Álvarez-Gigli , Ramón Robledano , Agustín España","doi":"10.1016/j.medcle.2024.01.041","DOIUrl":"10.1016/j.medcle.2024.01.041","url":null,"abstract":"<div><h3>Background</h3><p>An association between granuloma annulare (GA) and dyslipidaemia has been reported. Adipophilin expression may play a plausible role as a cutaneous biomarker for dyslipidaemia in patients with GA; however, this potential link remains to be explored.</p></div><div><h3>Methods</h3><p>Patients with GA were identified at our hospital between January 1, 1990, and December 31, 2021, with a thorough review of their clinical and histological characteristics. Adipophilin staining was assessed in biopsies of GA lesions.</p></div><div><h3>Results</h3><p>A total of 107 patients with GA were included. The prevalence of dyslipidaemia in patients with positive adipophilin staining was clearly higher than in those with negative labelling (62.3% vs 13.3%). Relative to the dyslipidaemia risk for patients with negative adipophilin expression, the odds for patients with positive adipophilin expression were increased 10-fold (OR: 10.8; <em>p</em>-value<.01). We identified 23 incident cases of dyslipidaemia over a median follow-up period of 91 months among 54 patients with no history of dyslipidaemia. The patients with positive adipophilin expression showed a higher risk of developing dyslipidaemia (HR: 8.9; <em>p</em>-value<.01).</p></div><div><h3>Conclusions</h3><p>Patients with positive adipophilin staining in their GA biopsies were found to be associated with a higher risk for both baseline and incident dyslipidaemia.</p></div>","PeriodicalId":74154,"journal":{"name":"Medicina clinica (English ed.)","volume":"163 5","pages":"Pages 232-237"},"PeriodicalIF":0.0,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142162790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Recommendations update for the diagnosis and treatment of transthyretin variant amyloidosis (ATTRv) 转甲状腺素变异性淀粉样变性（ATTRv）诊断和治疗建议更新

Medicina clinica (English ed.)

Pub Date : 2024-09-06 DOI: 10.1016/j.medcle.2024.04.011

Juan González-Moreno , Lucía Galán Dávila , Esther Gonzalez-Lopez , Isabel Conceiçao

引用次数: 0

Diffuse idiopathic pulmonary neuroendocrine cell hiperplasia: a rare cause of lung nodules 弥漫性特发性肺神经内分泌细胞疱疹：肺结节的罕见病因

Medicina clinica (English ed.)

Pub Date : 2024-09-04 DOI: 10.1016/j.medcle.2024.03.020

Antonio Rosales-Castillo , Antonio Bustos-Merlo , Bélgica Márquez-Lobo

引用次数: 0

Effectiveness of tixagevimab/cilgavimab in reducing SARS-CoV-2 infections, hospitalizations and mortality in inmunocompromised patients 替沙吉单抗/西格维单抗在降低免疫力低下患者 SARS-CoV-2 感染率、住院率和死亡率方面的效果

Medicina clinica (English ed.)

Pub Date : 2024-09-04 DOI: 10.1016/j.medcle.2024.03.018

Marc Marti-Pastor , Ricardo Bou-Monterde , Lucia Ciancotti-Oliver , Marta Alcover-Pons , Aurora Amorós Cantero , Raquel Sánchez-Lopezosa , Neus Montañana-Rosell

Introduction

Inmunocompromised people have higher SARS-CoV-2 morbi-mortality and they are subsidiary to receive pre-exposure prophylaxis. The objective of this study is to evaluate the effectiveness of tixagevimab/cilgavimab (Evusheld) in preventing SARS-CoV-2 infections, hospitalizations and mortality in immunocompromised patients.

Materials and methods

119 immunocompromised people ≥18 years old eligible of receiving Evusheld were followed for 6 months. People with previous SARS-CoV-2 infection or incomplete vaccination regimen were exluded. A total of 19 people who received Evusheld were matched by propensity score, using a 1:1 ratio, with another 19 people who did not receive Evusheld.

Sociodemographic, related to SARS-CoV-2 risk factors and related to immunosuppression variables were included. The dependent variables were infection, hospitalization, and mortality related to SARS-CoV-2.

Statistical analyzes were performed using SPSS Statistics 19.0, STATA 11.0, and the R statistical package.

Results

In total, 4 people in the Evusheld group and 11 in the control group had SARS-CoV-2 infection, showing an incidence rate of 3.87 and 13.62 per 100 person-months, respectively. The HR (Hazard Ratio) was 0.29 (95% CI = 0.09−0.90) for SARS-CoV-2 infection, 0.37 (0.07−1.92) for SARS-CoV-2 hospitalization and, 0.23 (0.03−2.09) for SARS-CoV-2 mortality in the Evusheld group compared to control group.

Conclusions

This study demonstrates that Evusheld reduces the SARS-CoV-2 infections.

导言：免疫功能低下者的 SARS-CoV-2 死亡率较高，他们是接受暴露前预防的辅助人群。本研究的目的是评估替沙吉单抗/西格维单抗（Evusheld）在预防免疫功能低下患者 SARS-CoV-2 感染、住院和死亡方面的有效性。既往感染过 SARS-CoV-2 或疫苗接种程序不完整者除外。社会人口学变量、与SARS-CoV-2相关的危险因素变量和与免疫抑制相关的变量均包括在内。统计分析使用 SPSS Statistics 19.0、STATA 11.0 和 R 统计软件包进行。结果 Evusheld 组共有 4 人感染了 SARS-CoV-2，对照组共有 11 人感染了 SARS-CoV-2，发病率分别为每百人月 3.87 例和 13.62 例。与对照组相比，Evusheld 组的 SARS-CoV-2 感染率为 0.29（95% CI = 0.09-0.90），SARS-CoV-2 住院率为 0.37（0.07-1.92），SARS-CoV-2 死亡率为 0.23（0.03-2.09）。

{"title":"Effectiveness of tixagevimab/cilgavimab in reducing SARS-CoV-2 infections, hospitalizations and mortality in inmunocompromised patients","authors":"Marc Marti-Pastor , Ricardo Bou-Monterde , Lucia Ciancotti-Oliver , Marta Alcover-Pons , Aurora Amorós Cantero , Raquel Sánchez-Lopezosa , Neus Montañana-Rosell","doi":"10.1016/j.medcle.2024.03.018","DOIUrl":"10.1016/j.medcle.2024.03.018","url":null,"abstract":"<div><h3>Introduction</h3><div>Inmunocompromised people have higher SARS-CoV-2 morbi-mortality and they are subsidiary to receive pre-exposure prophylaxis. The objective of this study is to evaluate the effectiveness of tixagevimab/cilgavimab (Evusheld) in preventing SARS-CoV-2 infections, hospitalizations and mortality in immunocompromised patients.</div></div><div><h3>Materials and methods</h3><div>119 immunocompromised people ≥18 years old eligible of receiving Evusheld were followed for 6 months. People with previous SARS-CoV-2 infection or incomplete vaccination regimen were exluded. A total of 19 people who received Evusheld were matched by propensity score, using a 1:1 ratio, with another 19 people who did not receive Evusheld.</div><div>Sociodemographic, related to SARS-CoV-2 risk factors and related to immunosuppression variables were included. The dependent variables were infection, hospitalization, and mortality related to SARS-CoV-2.</div><div>Statistical analyzes were performed using SPSS Statistics 19.0, STATA 11.0, and the R statistical package.</div></div><div><h3>Results</h3><div>In total, 4 people in the Evusheld group and 11 in the control group had SARS-CoV-2 infection, showing an incidence rate of 3.87 and 13.62 per 100 person-months, respectively. The HR (Hazard Ratio) was 0.29 (95% CI = 0.09−0.90) for SARS-CoV-2 infection, 0.37 (0.07−1.92) for SARS-CoV-2 hospitalization and, 0.23 (0.03−2.09) for SARS-CoV-2 mortality in the Evusheld group compared to control group.</div></div><div><h3>Conclusions</h3><div>This study demonstrates that Evusheld reduces the SARS-CoV-2 infections.</div></div>","PeriodicalId":74154,"journal":{"name":"Medicina clinica (English ed.)","volume":"163 6","pages":"Pages 275-280"},"PeriodicalIF":0.0,"publicationDate":"2024-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142315412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Medicina clinica (English ed.)

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀